SG49753A1 - Identification of a novel human receptor tyrosine kinase gene - Google Patents

Identification of a novel human receptor tyrosine kinase gene

Info

Publication number
SG49753A1
SG49753A1 SG1996004783A SG1996004783A SG49753A1 SG 49753 A1 SG49753 A1 SG 49753A1 SG 1996004783 A SG1996004783 A SG 1996004783A SG 1996004783 A SG1996004783 A SG 1996004783A SG 49753 A1 SG49753 A1 SG 49753A1
Authority
SG
Singapore
Prior art keywords
receptor
receptor tyrosine
novel human
tyrosine kinase
identification
Prior art date
Application number
SG1996004783A
Other languages
English (en)
Inventor
Miguel Eduardo Carrion
Bruce Israel Terman
Original Assignee
American Cyanamid Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by American Cyanamid Co filed Critical American Cyanamid Co
Publication of SG49753A1 publication Critical patent/SG49753A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/71—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
SG1996004783A 1991-02-22 1992-02-20 Identification of a novel human receptor tyrosine kinase gene SG49753A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US65723691A 1991-02-22 1991-02-22

Publications (1)

Publication Number Publication Date
SG49753A1 true SG49753A1 (en) 1998-06-15

Family

ID=24636385

Family Applications (1)

Application Number Title Priority Date Filing Date
SG1996004783A SG49753A1 (en) 1991-02-22 1992-02-20 Identification of a novel human receptor tyrosine kinase gene

Country Status (8)

Country Link
EP (1) EP0536350B1 (da)
AT (1) ATE221915T1 (da)
CA (1) CA2083401C (da)
DE (1) DE69232718T2 (da)
DK (1) DK0536350T3 (da)
ES (1) ES2180535T3 (da)
SG (1) SG49753A1 (da)
WO (1) WO1992014748A1 (da)

Families Citing this family (66)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6582959B2 (en) 1991-03-29 2003-06-24 Genentech, Inc. Antibodies to vascular endothelial cell growth factor
US5367057A (en) 1991-04-02 1994-11-22 The Trustees Of Princeton University Tyrosine kinase receptor flk-2 and fragments thereof
WO1993015201A1 (en) * 1992-01-22 1993-08-05 New England Deaconess Hospital Novel protein tyrosine kinases
US6331302B1 (en) 1992-01-22 2001-12-18 Genentech, Inc. Protein tyrosine kinase agonist antibodies
US5635177A (en) * 1992-01-22 1997-06-03 Genentech, Inc. Protein tyrosine kinase agonist antibodies
US5965132A (en) 1992-03-05 1999-10-12 Board Of Regents, The University Of Texas System Methods and compositions for targeting the vasculature of solid tumors
US6824777B1 (en) 1992-10-09 2004-11-30 Licentia Ltd. Flt4 (VEGFR-3) as a target for tumor imaging and anti-tumor therapy
US6107046A (en) * 1992-10-09 2000-08-22 Orion Corporation Antibodies to Flt4, a receptor tyrosine kinase and uses thereof
US5776755A (en) * 1992-10-09 1998-07-07 Helsinki University Licensing, Ltd. FLT4, a receptor tyrosine kinase
ATE348110T1 (de) * 1992-10-28 2007-01-15 Genentech Inc Hvegf rezeptor als vegf antagonist
US6872699B2 (en) 1992-11-13 2005-03-29 Max-Planck-Gesellschaft Zur Foerderung Der Wissenschaften, E.V. Truncated Flk-1 receptor protein, methods of use and a recombinant vector containing a nucleotide encoding the truncated Flk-1 protein
US5981569A (en) * 1992-11-13 1999-11-09 Yissum Research Development Company Of The Hebrew University Of Jerusalem Substituted phenylacrylonitrile compounds and compositions thereof for the treatment of disease
US5712395A (en) * 1992-11-13 1998-01-27 Yissum Research Development Corp. Compounds for the treatment of disorders related to vasculogenesis and/or angiogenesis
US5792771A (en) * 1992-11-13 1998-08-11 Sugen, Inc. Quinazoline compounds and compositions thereof for the treatment of disease
US5763441A (en) * 1992-11-13 1998-06-09 Sugen, Inc. Compounds for the treatment of disorders related to vasculogenesis and/or angiogenesis
US6177401B1 (en) 1992-11-13 2001-01-23 Max-Planck-Gesellschaft Zur Forderung Der Wissenschaften Use of organic compounds for the inhibition of Flk-1 mediated vasculogenesis and angiogenesis
ATE281469T1 (de) 1993-03-25 2004-11-15 Merck & Co Inc Inhibitor des wachstumsfaktors für gefäss- endothelzellen
US6001621A (en) * 1993-11-23 1999-12-14 Genetech, Inc. Protein tyrosine kinases
AU697142B2 (en) 1993-11-23 1998-10-01 Genentech Inc. Protein tyrosine kinases named Rse
US5840301A (en) * 1994-02-10 1998-11-24 Imclone Systems Incorporated Methods of use of chimerized, humanized, and single chain antibodies specific to VEGF receptors
US5861499A (en) 1994-02-10 1999-01-19 Imclone Systems Incorporated Nucleic acid molecules encoding the variable or hypervariable region of a monoclonal antibody that binds to an extracellular domain
US6811779B2 (en) 1994-02-10 2004-11-02 Imclone Systems Incorporated Methods for reducing tumor growth with VEGF receptor antibody combined with radiation and chemotherapy
US6448077B1 (en) * 1994-02-10 2002-09-10 Imclone Systems, Inc. Chimeric and humanized monoclonal antibodies specific to VEGF receptors
DE69434538T2 (de) 1994-03-08 2006-08-10 Human Genome Sciences, Inc. Vaskulärer endothelialer Wachstumsfaktor 2
US7153827B1 (en) 1994-03-08 2006-12-26 Human Genome Sciences, Inc. Vascular endothelial growth factor 2 and methods of use
US6734285B2 (en) 1994-03-08 2004-05-11 Human Genome Sciences, Inc. Vascular endothelial growth factor 2 proteins and compositions
US5932540A (en) 1994-03-08 1999-08-03 Human Genome Sciences, Inc. Vascular endothelial growth factor 2
US6040157A (en) 1994-03-08 2000-03-21 Human Genome Sciences, Inc. Vascular endothelial growth factor 2
US6608182B1 (en) 1994-03-08 2003-08-19 Human Genome Sciences, Inc. Human vascular endothelial growth factor 2
US7109308B1 (en) 1994-03-08 2006-09-19 Human Genome Sciences, Inc. Antibodies to human vascular endothelial growth factor 2
US7186688B1 (en) 1994-03-08 2007-03-06 Human Genome Sciences, Inc. Methods of stimulating angiogenesis in a patient by administering vascular endothelial growth factor 2
GB9410534D0 (en) * 1994-05-26 1994-07-13 Lynxvale Ltd Improvements in or relating to growth factor inhibitors
EP1353952B1 (en) 1994-11-14 2007-04-11 Ludwig Institute For Cancer Research Flt4(vegfr-3) as a target for tumor imaging and anti-tumor therapy
EP0848755B2 (en) 1995-09-08 2011-02-09 Genentech, Inc. Vegf-related protein
US6994989B1 (en) 1995-11-08 2006-02-07 Immunex Corp. FLK-1 binding proteins
AU1116297A (en) 1995-11-08 1997-05-29 Immunex Corporation Flk-1 binding protein
US6716575B2 (en) * 1995-12-18 2004-04-06 Sugen, Inc. Diagnosis and treatment of AUR1 and/or AUR2 related disorders
US7119174B2 (en) 1995-12-18 2006-10-10 Sugen, Inc. Diagnosis and treatment of AUR1 and/or AUR2 related disorders
ATE315654T1 (de) * 1995-12-18 2006-02-15 Sugen Inc Diagnose und behandlung von mit aur-1 und/oder aur-2 assoziierten erkrankungen
GB9601640D0 (en) * 1996-01-26 1996-03-27 Cancer Res Campaign Tech Ligand directed enzyme prodrug therapy
US6100071A (en) * 1996-05-07 2000-08-08 Genentech, Inc. Receptors as novel inhibitors of vascular endothelial growth factor activity and processes for their production
US6750044B1 (en) 1996-10-17 2004-06-15 Genentech, Inc. Variants of vascular endothelial cell growth factor having antagonistic properties, nucleic acids encoding the same and host cells comprising those nucleic acids
WO1998058053A1 (en) 1997-06-18 1998-12-23 Merck & Co., Inc. Human receptor tyrosine kinase, kdr
WO2000021560A1 (en) 1998-10-09 2000-04-20 Ludwig Institute For Cancer Research Flt4 (VEGFR-3) AS A TARGET FOR TUMOR IMAGING AND ANTI-TUMOR THERAPY
DE69926536T3 (de) 1998-12-22 2013-09-12 Genentech, Inc. Antagonisten von vaskular-endothelialen zellwachstumsfaktoren und ihre anwendung
US7396810B1 (en) 2000-08-14 2008-07-08 Oregon Health Sciences University Compositions and methods for treating cancer by modulating HER-2 and EGF receptors
US7393823B1 (en) 1999-01-20 2008-07-01 Oregon Health And Science University HER-2 binding antagonists
US7223724B1 (en) 1999-02-08 2007-05-29 Human Genome Sciences, Inc. Use of vascular endothelial growth factor to treat photoreceptor cells
CA2372053C (en) 1999-04-28 2008-09-02 Board Of Regents, The University Of Texas System Compositions and methods for cancer treatment by selectively inhibiting vegf
US6703020B1 (en) 1999-04-28 2004-03-09 Board Of Regents, The University Of Texas System Antibody conjugate methods for selectively inhibiting VEGF
GB9918057D0 (en) * 1999-07-30 1999-10-06 Univ Bristol Therapeutic agents
US7740841B1 (en) 2000-01-28 2010-06-22 Sunnybrook Health Science Center Therapeutic method for reducing angiogenesis
AU8473401A (en) 2000-08-04 2002-02-18 Human Genome Sciences, Inc. Vascular endothelial growth factor 2
US7402312B2 (en) 2001-04-13 2008-07-22 Human Genome Sciences, Inc. Antibodies to vascular endothelial growth factor 2 (VEGF-2)
CA2444632A1 (en) 2001-04-13 2002-10-24 Human Genome Sciences, Inc. Vascular endothelial growth factor 2
US7261876B2 (en) 2002-03-01 2007-08-28 Bracco International Bv Multivalent constructs for therapeutic and diagnostic applications
US8623822B2 (en) 2002-03-01 2014-01-07 Bracco Suisse Sa KDR and VEGF/KDR binding peptides and their use in diagnosis and therapy
US7211240B2 (en) 2002-03-01 2007-05-01 Bracco International B.V. Multivalent constructs for therapeutic and diagnostic applications
US20050100963A1 (en) 2002-03-01 2005-05-12 Dyax Corporation KDR and VEGF/KDR binding peptides and their use in diagnosis and therapy
US7985402B2 (en) 2002-03-01 2011-07-26 Bracco Suisse Sa Targeting vector-phospholipid conjugates
US7794693B2 (en) 2002-03-01 2010-09-14 Bracco International B.V. Targeting vector-phospholipid conjugates
WO2004078778A2 (en) 2003-03-03 2004-09-16 Dyax Corp. PEPTIDES THAT SPECIFICALLY BIND HGF RECEPTOR (cMet) AND USES THEREOF
ME00425B (me) 2003-05-30 2011-10-10 Genentech Inc Liječenje sa anti-vegf antitijelima
EP2377555A3 (en) 2004-11-18 2011-11-23 Imclone LLC Antibodies against vascular endothelial growth factor receptor-1
UY31478A1 (es) 2007-11-21 2009-07-17 Inhibicion del receptor para la proteina estimulante del macrofago (ron) y métodos para el tratamiento de lo mismo
CA2901226C (en) 2013-02-18 2020-11-17 Vegenics Pty Limited Vascular endothelial growth factor binding proteins

Also Published As

Publication number Publication date
EP0536350A4 (en) 1994-03-22
ATE221915T1 (de) 2002-08-15
EP0536350B1 (en) 2002-08-07
CA2083401C (en) 2003-03-25
DE69232718D1 (de) 2002-09-12
CA2083401A1 (en) 1992-08-23
DE69232718T2 (de) 2003-04-03
DK0536350T3 (da) 2002-09-02
EP0536350A1 (en) 1993-04-14
WO1992014748A1 (en) 1992-09-03
ES2180535T3 (es) 2003-02-16

Similar Documents

Publication Publication Date Title
SG49753A1 (en) Identification of a novel human receptor tyrosine kinase gene
MX9702307A (es) Pirrolo (2,3-d)pirimidinas y su uso.
EP0653940A4 (en) GLIALMITOGENIC FACTORS, THEIR PRODUCTION AND USE.
DK0836605T3 (da) Pyrrolopyrimidiner og fremgangsmåder til deres fremstilling
CY2451B1 (en) Fused heterocyclic compunds as protein tyrosine kinase inhibitors.
AU5330698A (en) Fused polycyclic 2-aminopyrimidine derivatives, their preparation and their use as protein tyrosine kinase inhibitors
CA2079585A1 (en) Ligand for the neu gene product
NO971038L (no) Pyrimido£5,4-d|pyrimidiner, legemidler inneholdende disse forbindelser, deres anvendelse og fremgangsmåte for fremstilling av dem
CA2366932A1 (en) Cyclic protein tyrosine kinase inhibitors
EP0915989A4 (en) KINASE PROTEIN ASSAYS USING FLUORESCENT PROTEIN SUBSTRATES
FI972492A0 (fi) Imidatsolijohdoksia proteiinikinaasien, erityisesti EGF-R-tyrosiinikinaasin, inhibiittoreina
DE69932153D1 (en) Phosphodiesterase 10
NO971341L (no) Promoter for reseptor tyrosinkinase TIE
EP0854185A3 (en) Assay receptor proteins and ligands
BR9910787A (pt) Métodos e composições úteis para modulação deangiogênese usando tirosina cinase src
ES8705897A1 (es) Un metodo para producir una proteina capaz de modular la actividad fisiologica de celulas que tienen receptores de diazepam.
AU7241296A (en) Modified protein kinase a-specific oligonucleotides and methods of their use
DE60139113D1 (de) 18477, eine menschliche proteinkinase und deren verwendung
UA41278C2 (uk) Антимікробний білок, рекомбінантна днк, що містить послідовність, яка кодує антимікробний білок, антимікробна композиція
WO2001036602A3 (en) Pak5 a member of the p21-activated kinase (pak) protein family, nucleic acids and methods related to the same
DE69233330D1 (de) Verwendung eines Inhibitors von Tau/Neurofilament-Proteinkinase PK40
ATE293163T1 (de) Cyclin e spezifische konstrukte und komplexe
BG103342A (en) Gax protein domains-containing polypeptides included in the presented transcription and/or interrelated to other proteins corresponding to neucleinic acids, and their application
EP1482049A3 (en) A protein tyrosine kinase.
SE9604439D0 (sv) New receptor